Pillar Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Pillar Biosciences's estimated annual revenue is currently $13.9M per year.
- Pillar Biosciences received $18.0M in venture funding in May 2016.
- Pillar Biosciences's estimated revenue per employee is $155,000
- Pillar Biosciences's total funding is $65.9M.
- Pillar Biosciences has 90 Employees.
- Pillar Biosciences grew their employee count by 11% last year.
Pillar Biosciences Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Pillar Biosciences?
Pillar Biosciences aims to "Make Precision Medicine Accessible" by developing and manufacturing targeted next-generation sequencing (NGS)-based assays and software for today's high-throughput specialty NGS laboratories. Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics. In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
Number of Employees
Employee Growth %
Pillar Biosciences News
Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics, in response to emailed questions from MedCity News. Why did you join Pillar Biosciences? I am incredibly impressed with the technology and the a ...
Pillar Biosciences Inc., a Natick, MA-based startup specialized in next generation sequencing (“NGS”)-based clinical oncology testing, received US$18m in venture capital. ORI Capital’s ORI Healthcare Fund made the investment. The company intends to use the funds to continue its R&D efforts in ...
Pillar Biosciences, a Natick, Mass.- and Shanghai, China-based NGS clinical cancer diagnostics company, closed a $29.7m Series C financing. The round was led by ORI Healthcare Fund. The company intends to use the funds to accelerate the expansion of in vitro diagnostic and research use only pa ...
BOSTON, May 30, 2019 /PRNewswire/ -- Pillar Biosciences, a clinical cancer diagnostics company based near Boston, MA, announced today ...
SAN FRANCISCO, Jan. 10, 2019 /PRNewswire/ -- Pillar Biosciences, Inc., a clinical cancer diagnostics company based in Boston, MA, USA ...
... Pillar Biosciences, Medicover, and Hightech Gründerfund, Europe's leading startup investor, McDermott Will & Emery as well as Aescuvest.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Pillar Biosciences Funding
|2016-05-12||$18.0M||Undisclosed||ORI Healthcare Fund L.P||Article|